Business & Policy

Innovation meets Life Sciences: The Future of Regenerative Medicine and its Investment Environment in Japan

Japan’s efforts in revitalizing the fields of regenerative medicine and life sciences have seen significant progress, beginning with Dr. Shinya Yamanaka’s groundbreaking research on iPS cells, which won him the Nobel Prize, their clinical applications, and the nation’s recent revision of the Pharmaceutical Affairs Law. The University of Tokyo Edge Capital (UTEC), a seed/early stage technology-focused venture capital firm, finds and invests in those firms with the potential to bring revolutionary technology to the forefront of the field of regenerative medicine. With the leadership of Dr. Maiko Katadae, recipient of Nikkei’s Woman of the Year award and partner at UTEC, the firm now manages $280 million in venture capital funds. Dr. Katadae calls upon her scientific background to guide the firm’s investment decisions and to fulfill her responsibility in due diligence of life sciences-related technologies. In this lecture, Dr. Katadae discusses Japan’s environment for investment in venture capital and life sciences, and touches upon both the importance of regenerative medicine and its implications moving forward.

Dr. Maiko Katadae
, Partner, The University of Tokyo Edge Capital (UTEC)

Jim Impoco
, Editor-in-Chief, Newsweek

You will need Adobe Flash Player to view the webcasts, please click here to download Adobe Flash Player.

Calendar of Events

February 2018

S M T W Th F S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28      
All content © 2018, Japan Society, unless otherwise noted. |
333 East 47th Street New York, NY 10017 Phone: 212.832.1155 |
Credits | Press | Contact Us | Privacy Policy